U.S. Markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    44.90
    -0.81 (-1.77%)
     
  • Gold

    1,813.90
    +2.70 (+0.15%)
     
  • Silver

    23.42
    -0.02 (-0.09%)
     
  • EUR/USD

    1.1910
    -0.0009 (-0.0715%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3347
    -0.0036 (-0.2696%)
     
  • USD/JPY

    104.2590
    -0.1810 (-0.1733%)
     
  • BTC-USD

    16,869.62
    -1,109.56 (-6.17%)
     
  • CMC Crypto 200

    329.34
    -41.18 (-11.11%)
     
  • FTSE 100

    6,362.93
    -28.16 (-0.44%)
     
  • Nikkei 225

    26,537.31
    +240.45 (+0.91%)
     

SHAREHOLDER ALERT: BMRN ACB ICPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

·3 min read

NEW YORK, NY / ACCESSWIRE / November 20, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=11107&wire=1.
Lead Plaintiff Deadline: November 24, 2020
Class Period: February 28, 2020 - August 18, 2020

Allegations against BMRN include that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Aurora Cannabis Inc. (NYSE:ACB)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/aurora-cannabis-inc-loss-submission-form-2?prid=11107&wire=1.
Lead Plaintiff Deadline: December 1, 2020
Class Period: February 13, 2020 - September 4, 2020

Allegations against ACB include that: (i) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (ii) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (iii) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11107&wire=1.
Lead Plaintiff Deadline: January 4, 2021
Class Period: September 28, 2019 - October 7, 2020

Allegations against ICPT include that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

To learn more, contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/617744/SHAREHOLDER-ALERT-BMRN-ACB-ICPT-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines